Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NeuroMetrix, Inc. (NURO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.96-0.35 (-4.79%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.31
Open7.26
Bid6.87 x 1000
Ask7.15 x 900
Day's Range6.89 - 7.32
52 Week Range1.90 - 38.75
Volume215,512
Avg. Volume1,426,312
Market Cap26.47M
Beta (5Y Monthly)2.79
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateApr 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 28, 2007
1y Target EstN/A
  • GlobeNewswire

    NeuroMetrix Reports Q3 2021 Financial Results

    WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: Revenue of $2.1 million was up slightly from Q3 2020. Gross margin on revenue was $1.4 million, a 70.0% gross margin rate. This was a decrease of 3.6 percentage points from $1.5 m

  • GlobeNewswire

    NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care

    WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell will be responsible for growing the Company's DPNCheck® business with a primary focus on the Medicare Advantage population, and more broadly, expanding the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast

  • Simply Wall St.

    Those who invested in NeuroMetrix (NASDAQ:NURO) a year ago are up 453%

    Some NeuroMetrix, Inc. ( NASDAQ:NURO ) shareholders are probably rather concerned to see the share price fall 55% over...

Advertisement
Advertisement